ME01040B - 2-(1H-INDOLlLSULFANIL)-BENZIL AMIN DERIVATI KAO SSRI - Google Patents

2-(1H-INDOLlLSULFANIL)-BENZIL AMIN DERIVATI KAO SSRI

Info

Publication number: ME01040B
Authority: ME; Montenegro
Prior art keywords: indol; ylsulfanyl; amine; benzyl; methyl
Prior art date: 2003-12-23

Application number

MEP-2008-66A

Other languages

English (en)

French (fr)

Unknown language (me)

Inventor

Jan Kehler

Karsten Juhl

Jimmy Sejberg

Morten Bang NØRGAARD

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-23

Filing date

2004-12-21

Publication date

2010-05-07

2004-12-21 Application filed by H Lundbeck As filed Critical H Lundbeck As

2004-12-21 Priority claimed from EP04803045A external-priority patent/EP1701940B1/de

2010-05-07 Publication of ME01040B publication Critical patent/ME01040B/me

Links

-1 2-(1h-indolylsulfanyl)-benzyl Chemical group 0.000 title claims 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 8
229910052717 sulfur Inorganic materials 0.000 claims 8
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 7
229910052739 hydrogen Inorganic materials 0.000 claims 7
239000001257 hydrogen Substances 0.000 claims 7
150000001875 compounds Chemical class 0.000 claims 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
125000004434 sulfur atom Chemical group 0.000 claims 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 5
125000004429 atom Chemical group 0.000 claims 5
201000010099 disease Diseases 0.000 claims 5
208000035475 disorder Diseases 0.000 claims 5
229910052736 halogen Inorganic materials 0.000 claims 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
125000004093 cyano group Chemical group *C#N 0.000 claims 4
150000002367 halogens Chemical group 0.000 claims 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
208000017194 Affective disease Diseases 0.000 claims 3
208000019022 Mood disease Diseases 0.000 claims 3
229910052757 nitrogen Inorganic materials 0.000 claims 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
208000019901 Anxiety disease Diseases 0.000 claims 2
208000020401 Depressive disease Diseases 0.000 claims 2
208000002193 Pain Diseases 0.000 claims 2
206010041250 Social phobia Diseases 0.000 claims 2
208000027520 Somatoform disease Diseases 0.000 claims 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
150000001412 amines Chemical class 0.000 claims 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
125000005842 heteroatom Chemical group 0.000 claims 2
150000002475 indoles Chemical class 0.000 claims 2
125000001041 indolyl group Chemical group 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
239000001301 oxygen Chemical group 0.000 claims 2
208000027753 pain disease Diseases 0.000 claims 2
208000019906 panic disease Diseases 0.000 claims 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
150000003839 salts Chemical class 0.000 claims 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
239000011593 sulfur Chemical group 0.000 claims 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
HIGNJFZAWKAXNC-UHFFFAOYSA-N 1-[2-[(4,6-difluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylmethanamine Chemical compound CNCC1=CC=CC=C1SC1=CNC2=CC(F)=CC(F)=C12 HIGNJFZAWKAXNC-UHFFFAOYSA-N 0.000 claims 1
ADYCPRDBFKAHRJ-UHFFFAOYSA-N 1-[2-[(5,6-dimethoxy-1h-indol-3-yl)sulfanyl]-5-fluorophenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=CC=C1SC1=CNC2=CC(OC)=C(OC)C=C12 ADYCPRDBFKAHRJ-UHFFFAOYSA-N 0.000 claims 1
LZTNSIXIYPOJFF-UHFFFAOYSA-N 1-[2-[(6-bromo-1h-indol-3-yl)sulfanyl]-5-methylphenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C)=CC=C1SC1=CNC2=CC(Br)=CC=C12 LZTNSIXIYPOJFF-UHFFFAOYSA-N 0.000 claims 1
GSBZMNZLAQIZCJ-UHFFFAOYSA-N 1-[2-[(6-methoxy-1h-indol-3-yl)sulfanyl]-5-methylphenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C)=CC=C1SC1=CNC2=CC(OC)=CC=C12 GSBZMNZLAQIZCJ-UHFFFAOYSA-N 0.000 claims 1
YKQJAJVXFHNXMV-UHFFFAOYSA-N 1-[5-fluoro-2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=CC=C1SC1=CNC2=CC(F)=CC=C12 YKQJAJVXFHNXMV-UHFFFAOYSA-N 0.000 claims 1
DTJBMIHLKFIBLI-UHFFFAOYSA-N 1-[5-fluoro-2-[[6-(trifluoromethyl)-1h-indol-3-yl]sulfanyl]phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(F)=CC=C1SC1=CNC2=CC(C(F)(F)F)=CC=C12 DTJBMIHLKFIBLI-UHFFFAOYSA-N 0.000 claims 1
208000008811 Agoraphobia Diseases 0.000 claims 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
208000008035 Back Pain Diseases 0.000 claims 1
208000020925 Bipolar disease Diseases 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
208000001640 Fibromyalgia Diseases 0.000 claims 1
206010019233 Headaches Diseases 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
206010033664 Panic attack Diseases 0.000 claims 1
208000027089 Parkinsonian disease Diseases 0.000 claims 1
206010034010 Parkinsonism Diseases 0.000 claims 1
206010034912 Phobia Diseases 0.000 claims 1
201000009916 Postpartum depression Diseases 0.000 claims 1
208000028017 Psychotic disease Diseases 0.000 claims 1
208000007613 Shoulder Pain Diseases 0.000 claims 1
206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
QXPFRQKAHVYKNS-UHFFFAOYSA-N [2-[(6-fluoro-1h-indol-3-yl)sulfanyl]phenyl]methanamine Chemical compound NCC1=CC=CC=C1SC1=CNC2=CC(F)=CC=C12 QXPFRQKAHVYKNS-UHFFFAOYSA-N 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
229940058679 baza Drugs 0.000 claims 1
WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000024732 dysthymic disease Diseases 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
239000012458 free base Substances 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
231100000869 headache Toxicity 0.000 claims 1
208000024714 major depressive disease Diseases 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
FMEBXJPFHMJAMM-UHFFFAOYSA-N n,n-dimethyl-1-[2-[(6-methyl-1h-indol-3-yl)sulfanyl]phenyl]methanamine Chemical compound CN(C)CC1=CC=CC=C1SC1=CNC2=CC(C)=CC=C12 FMEBXJPFHMJAMM-UHFFFAOYSA-N 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
208000028173 post-traumatic stress disease Diseases 0.000 claims 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
201000001716 specific phobia Diseases 0.000 claims 1
208000022170 stress incontinence Diseases 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MEP-2008-66A 2003-12-23 2004-12-21 2-(1H-INDOLlLSULFANIL)-BENZIL AMIN DERIVATI KAO SSRI ME01040B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US53259303P	2003-12-23	2003-12-23
DKPA200301923		2003-12-23
EP04803045A EP1701940B1 (de)	2003-12-23	2004-12-21	2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
PCT/DK2004/000894 WO2005061455A1 (en)	2003-12-23	2004-12-21	2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

Publications (1)

Publication Number	Publication Date
ME01040B true ME01040B (me)	2010-05-07

Family

ID=36603121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2008-66A ME01040B (me)	2003-12-23	2004-12-21	2-(1H-INDOLlLSULFANIL)-BENZIL AMIN DERIVATI KAO SSRI

Country Status (23)

Country	Link
EP (1)	EP1860100B1 (de)
KR (2)	KR100872022B1 (de)
CN (2)	CN101372474A (de)
AR (1)	AR046978A1 (de)
AT (1)	ATE500220T1 (de)
CA (1)	CA2551168C (de)
DE (1)	DE602004031680D1 (de)
DK (1)	DK1860100T3 (de)
EA (2)	EA012752B1 (de)
ES (1)	ES2362237T3 (de)
IS (2)	IS2551B (de)
ME (1)	ME01040B (de)
MY (1)	MY143038A (de)
NO (1)	NO336676B1 (de)
NZ (1)	NZ547046A (de)
PL (1)	PL1860100T4 (de)
PT (1)	PT1860100E (de)
RS (1)	RS51899B (de)
SG (1)	SG141463A1 (de)
SI (1)	SI1860100T1 (de)
TW (1)	TWI347183B (de)
UA (1)	UA82920C2 (de)
ZA (1)	ZA200705870B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101224201B (zh) *	2007-01-18	2011-10-05	和泓生物技术（上海）有限公司	多巴胺转运蛋白和去甲肾上腺素转运蛋白双重抑制剂的应用
EP2606031B1 (de) *	2010-08-20	2017-09-27	Amira Pharmaceuticals, Inc.	Autotaxin-hemmer und anwendungen davon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3803143A (en)	1969-09-08	1974-04-09	Eisai Co Ltd	6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en)	1969-09-22	1977-04-19	Merck & Co., Inc.	Phenylthioaralkylamines
US4055665A (en)	1974-11-25	1977-10-25	Merck & Co., Inc.	Treating arrythmia with phenylthioaralkylamines
US4056632A (en)	1975-07-21	1977-11-01	Burroughs Wellcome Co.	2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
EP0396827A1 (de)	1989-05-09	1990-11-14	SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu	2-Phenylthiobenzylamin-Derivate und Säureadditionssalze davon
GB8912971D0 (en)	1989-06-06	1989-07-26	Wellcome Found	Halogen substituted diphenylsulfides
GB9126311D0 (en)	1991-12-11	1992-02-12	Wellcome Found	Substituted diphenylsulfides
CZ293595A3 (cs)	1995-11-09	1999-12-15	Farmak A. S.	Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) *	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
AU4091697A (en) *	1996-08-27	1998-03-19	American Home Products Corporation	4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
WO2000066537A1 (en)	1999-04-30	2000-11-09	The Trustees Of The University Of Pennsylvania	Spect imaging agents for serotonin transporters
US6410736B1 (en)	1999-11-29	2002-06-25	Pfizer Inc.	Biaryl ether derivatives useful as monoamine reuptake inhibitors
US6436938B1 (en)	2001-01-22	2002-08-20	Pfizer Inc.	Combination treatment for depression

2004
- 2004-12-16 TW TW093139107A patent/TWI347183B/zh not_active IP Right Cessation
- 2004-12-21 SG SG200802454-9A patent/SG141463A1/en unknown
- 2004-12-21 EA EA200702258A patent/EA012752B1/ru not_active IP Right Cessation
- 2004-12-21 ZA ZA200705870A patent/ZA200705870B/xx unknown
- 2004-12-21 EA EA200601226A patent/EA010666B1/ru not_active IP Right Cessation
- 2004-12-21 MY MYPI20045285A patent/MY143038A/en unknown
- 2004-12-21 ES ES07017638T patent/ES2362237T3/es not_active Expired - Lifetime
- 2004-12-21 PL PL07017638T patent/PL1860100T4/pl unknown
- 2004-12-21 CN CNA2008101447939A patent/CN101372474A/zh active Pending
- 2004-12-21 AT AT07017638T patent/ATE500220T1/de active
- 2004-12-21 ME MEP-2008-66A patent/ME01040B/me unknown
- 2004-12-21 DE DE602004031680T patent/DE602004031680D1/de not_active Expired - Lifetime
- 2004-12-21 AR ARP040104830A patent/AR046978A1/es not_active Application Discontinuation
- 2004-12-21 RS RS20110213A patent/RS51899B/sr unknown
- 2004-12-21 SI SI200431671T patent/SI1860100T1/sl unknown
- 2004-12-21 CA CA2551168A patent/CA2551168C/en not_active Expired - Fee Related
- 2004-12-21 EP EP07017638A patent/EP1860100B1/de not_active Expired - Lifetime
- 2004-12-21 UA UAA200607149A patent/UA82920C2/uk unknown
- 2004-12-21 DK DK07017638.3T patent/DK1860100T3/da active
- 2004-12-21 NZ NZ547046A patent/NZ547046A/en not_active IP Right Cessation
- 2004-12-21 KR KR1020067011175A patent/KR100872022B1/ko not_active Expired - Fee Related
- 2004-12-21 KR KR1020087021534A patent/KR20080092471A/ko not_active Withdrawn
- 2004-12-21 PT PT07017638T patent/PT1860100E/pt unknown
- 2004-12-21 CN CN200480038470A patent/CN100591666C/zh not_active Expired - Fee Related
2006
- 2006-05-15 IS IS8467A patent/IS2551B/is unknown
- 2006-07-24 NO NO20063405A patent/NO336676B1/no not_active IP Right Cessation
2009
- 2009-06-05 IS IS8827A patent/IS2815B/is unknown

Also Published As

Publication number	Publication date
IS8467A (is)	2006-05-15
EA012752B1 (ru)	2009-12-30
SI1860100T1 (sl)	2011-06-30
PL1860100T3 (pl)	2011-07-29
HK1103075A1 (zh)	2007-12-14
CA2551168A1 (en)	2005-07-07
IS2815B (is)	2012-11-15
SG141463A1 (en)	2008-04-28
PT1860100E (pt)	2011-05-25
KR100872022B1 (ko)	2008-12-05
CN1898204A (zh)	2007-01-17
CA2551168C (en)	2011-09-13
ATE500220T1 (de)	2011-03-15
MY143038A (en)	2011-02-28
CN100591666C (zh)	2010-02-24
KR20060118529A (ko)	2006-11-23
EP1860100A3 (de)	2007-12-05
IS8827A (is)	2009-06-05
CN101372474A (zh)	2009-02-25
AR046978A1 (es)	2006-01-04
EA200601226A1 (ru)	2006-10-27
NO20063405L (no)	2006-07-24
UA82920C2 (en)	2008-05-26
RS51899B (sr)	2012-02-29
EP1860100A2 (de)	2007-11-28
NZ547046A (en)	2010-04-30
DE602004031680D1 (de)	2011-04-14
ZA200705870B (en)	2009-09-30
NO336676B1 (no)	2015-10-19
PL1860100T4 (pl)	2011-09-30
TW200607499A (en)	2006-03-01
DK1860100T3 (da)	2011-06-14
TWI347183B (en)	2011-08-21
EA010666B1 (ru)	2008-10-30
KR20080092471A (ko)	2008-10-15
EA200702258A1 (ru)	2008-02-28
ES2362237T3 (es)	2011-06-30
EP1860100B1 (de)	2011-03-02
IS2551B (is)	2009-10-15

Publication	Publication Date	Title
HRP20110400T1 (hr)	2011-06-30	Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri
NO20063620L (no)	2006-10-06	Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20056132L (no)	2006-01-26	Krystallinsk form av beta2 adrenergisk receptoragonist
AR039568A1 (es)	2005-02-23	Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa, composicion farmaceutica y procedimiento de preparacion del compuesto
AR061846A1 (es)	2008-09-24	Compuestos heteroaromaticos de azol inhibidores selectivos de la pde10a, composiciones farmaceuticas que los contienen y usos para tratar trastornos asociados al cns.
AR036045A1 (es)	2004-08-04	Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, su empleo para la preparacion de un medicamento, asi como composiciones farmaceuticas que las contienen
AR068413A2 (es)	2009-11-18	Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AP2002002481A0 (en)	2002-06-30	Biaryl ether derivatives useful as monoamine reuptake inhibitors.
AR041566A1 (es)	2005-05-18	Derivados de indol utiles para el tratamiento de enfermedades
ATE496620T1 (de)	2011-02-15	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
PE20091403A1 (es)	2009-09-28	Derivados de carboxamidas n-azabiciclicas y su preparacion
BRPI0415746A (pt)	2006-12-19	derivados de amida
NO20075623L (no)	2008-01-17	Benzodioksan- og benzodioksolanderivater og deres anvendelse
NO20062139L (no)	2006-07-21	Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
TW200734322A (en)	2007-09-16	Indole derivatives exhibiting PGD2 receptor antagonism
WO2009080836A3 (en)	2009-09-17	Macrocyclic indoles as hepatitis c virus inhibitors
PE20080277A1 (es)	2008-04-11	Derivados de azaindol espirociclicos y sustituidos
RU2011137131A (ru)	2013-03-20	Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
MX2007013021A (es)	2008-01-11	Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
ES2174757B1 (es)	2003-11-01	Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
SG164283A1 (en)	2010-09-29	New benzimidazole derivatives
TW200616953A (en)	2006-06-01	Indole, indazole or indoline derivatives
EA201170153A1 (ru)	2011-08-30	Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
ATE364044T1 (de)	2007-06-15	5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
NO20072005L (no)	2007-06-15	Nye heterocykliske amider